HDA 2023 Traceability Seminar: Industry Identifies Critical DSCSA Implementation Gaps

The Healthcare Distribution Alliance's 2023 Traceability Seminar revealed persistent compliance gaps in wholesale drug distributors' DSCSA readiness ahead of the November 27, 2024 enforcement deadline. Industry feedback centered on three technical areas: EPCIS data interoperability, verification router system (VRS) limitations, and authorized trading partner (ATP) database fragmentation.

Regulatory Context

The Drug Supply Chain Security Act (Public Law 113-54) mandates unit-level serialization and interoperable electronic tracing for prescription drugs. Under 21 CFR 582.20, wholesale distributors must verify product identifiers before distribution, maintain electronic product tracing data, and respond to verification requests within 24 hours. The November 27, 2024 deadline marks full enforcement of unit-level tracing requirements across the pharmaceutical supply chain.

FDA issued final guidance on DSCSA product tracing requirements in March 2023. The guidance clarifies that distributors must be able to accept EPCIS 1.2 formatted transaction data and verify serialized product identifiers against manufacturer-provided data before distribution.

Key Compliance Challenges Identified

EPCIS Data Exchange Failures

Wholesale distributors reported inconsistent EPCIS implementation across trading partners. The seminar documented cases where manufacturers and repackagers used different EPCIS namespaces, making automated data validation impossible. One distributor presented data showing 23% of incoming shipments contained malformed EPCIS files that required manual remediation.

The issue stems from EPCIS 1.2 allowing multiple valid formatting approaches. GS1 US published implementation guidelines in 2022, but adoption remains uneven. Distributors without the technical resources to parse multiple EPCIS variants face manual data entry, introducing compliance risk and operational delays.

Verification Router System Limitations

The VRS framework — intended to route product verification requests to the appropriate manufacturer — showed interoperability problems. Distributors reported VRS lookup failures on products from smaller manufacturers who have not yet registered serialized GTINs in the VRS directory.

Under 21 CFR 582.130, distributors must verify product identifiers when they suspect illegitimate product or receive a request from FDA. VRS failures force distributors into manual verification workflows, contacting manufacturers directly. For high-volume distributors processing 10,000+ line items daily, this creates unsustainable operational burden.

Authorized Trading Partner Database Gaps

The ATP verification requirement under 21 CFR 582.115 requires distributors to verify their trading partners hold valid state licensure. HDA members identified no centralized ATP database covering all 50 states plus territories. Distributors must query individual state boards of pharmacy, NABP's LicenseeCheck (subscription required), or maintain internal databases.

State board of pharmacy websites vary in data format and update frequency. Seventeen states do not provide machine-readable license data, forcing manual verification. For distributors with 500+ active trading partners, quarterly ATP verification represents significant compliance overhead.

Operational Impact on Distributors

These three areas create immediate compliance risk for wholesale drug distributors:

Data quality: Malformed EPCIS data requires manual remediation, slowing receiving operations and increasing error rates.

Verification speed: VRS lookup failures and ATP verification gaps extend transaction times. Distributors cannot ship product until verification completes.

Resource allocation: Manual workarounds for interoperability failures require dedicated FTE resources. Mid-size distributors reported adding 2-3 compliance staff to manage DSCSA data exceptions.

Audit exposure: FDA inspections beginning in 2024 will examine EPCIS transaction records and ATP verification documentation. Gaps in either area constitute violations of 21 CFR 582.

What ColdChainCheck Data Shows

ColdChainCheck tracks 1,275 wholesale drug distributors and 3PLs across 51 jurisdictions. The average compliance score of 51/100 reflects persistent gaps in verifiable compliance signals — the same operational fragmentation HDA documented at the traceability seminar.

Only 63 entities (4.9%) hold NABP accreditation, which requires demonstrated systems for product tracing and supply chain security. The remaining 1,212 entities rely on state licensure alone, which does not assess DSCSA technical capabilities. This creates ATP verification burden: a distributor checking trading partner credentials cannot assume NABP accreditation or verify EPCIS readiness through public data.

The score distribution reveals readiness stratification. 28 entities (2.2%) scored 'Excellent' (81-100), indicating comprehensive compliance signals across FDA registration, multi-state licensure, and NABP accreditation. These entities likely invested early in EPCIS infrastructure and VRS integration. At the other end, 47 entities (3.7%) scored 'Poor' or 'Minimal' (0-40), showing limited verifiable compliance signals beyond home-state licensure.

73 entities have FDA recalls on record. Recall events often correlate with supply chain documentation failures — the type of data integrity problems EPCIS interoperability issues exacerbate.

Practical Steps for QA and Compliance Teams

• Audit your trading partner list against ColdChainCheck: Use the directory to identify distributors with limited compliance signals. Entities scoring below 40 warrant enhanced ATP verification — confirm current state licenses, request DSCSA technical capabilities documentation, and verify VRS registration.

• Prioritize NABP-accredited partners: Filter the directory for NABP accreditation status. The 63 accredited entities demonstrate third-party verified DSCSA systems. This reduces ATP verification burden and VRS interoperability risk.

• Cross-reference state licensure coverage: For distributors operating in multiple states, verify active licenses in each jurisdiction. ColdChainCheck tracks 25,665 state licenses across all entities. Expired or suspended licenses indicate compliance gaps that may extend to EPCIS capabilities.

• Monitor recall history: Entities with multiple FDA recalls may have systemic data integrity issues. ColdChainCheck flags all recalls on entity profiles. Review recall causes — supply chain documentation failures signal EPCIS interoperability problems.

ColdChainCheck continues tracking ATP-relevant compliance signals. For guidance on evaluating distributor DSCSA readiness, see the DSCSA compliance checklist.

Disclaimer: This article is for informational purposes only and does not constitute legal or regulatory advice. Verify all compliance requirements with your legal counsel and the relevant regulatory authorities.